Search results for "Recurso"

showing 10 items of 734 documents

Influence of training and a maximal exercise test in analytical variability of muscular, hepatic, and cardiovascular biochemical variables.

2014

Short, middle, and long-term exercise, as well as the relative intensity of the physical effort, may influence a broad array of laboratory results, and it is thereby of pivotal importance to appropriately differentiate the 'physiologic' from the 'pathological' effects of exercise. Therefore, the values of some biomarkers in physically active subjects may be cautiously interpreted since the results may fall outside the conventional reference ranges. It has been demonstrated that middle and long-term endurance and/or strenuous exercise triggers transient elevations of muscular and cardiac biomarkers. However, no data have been published about the effect of short-term maximal exercise test on …

AdultCalcitoninMalemedicine.medical_specialtyCardiac biomarkersCardiovascular biomarkersCalcitonin Gene-Related PeptideClinical BiochemistryPhysical ExertionPhysical medicine and rehabilitationReference ValuesInternal medicineNatriuretic Peptide BrainmedicineCreatine Kinase MB FormHumansAspartate AminotransferasesProtein PrecursorsMuscle SkeletalPathologicalExerciseRelative intensitybiologyL-Lactate Dehydrogenasebusiness.industryC-reactive proteinSkeletal muscleHeartGeneral Medicinegamma-GlutamyltransferaseLaboratory resultsPeptide FragmentsTroponinmedicine.anatomical_structureexercise; laboratory; biomarkersC-Reactive ProteinLiverCardiologybiology.proteinExercise TestPhysical EnduranceMaximal exerciseSedentary BehaviorbusinesslaboratoryBiomarkersScandinavian journal of clinical and laboratory investigation
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Erythrocyte Membrane Phosphatidylserine Exposure in Obesity

2008

It has been suggested that increased erythrocyte membrane phosphatidylserine (PS) exposure could contribute to hypercoagulability and hemorheological disturbances in obesity. The aim of our study was to evaluate PS exposure in obese patients and in a control group and to correlate this with hemorheological properties, i.e., erythrocyte aggregability (EA) and deformability, and to evaluate the effect of weight loss on these parameters. An anthropometric and analytical evaluation was performed at baseline and after 3 months on a diet (very low-calorie diet for 4 weeks and low-calorie diet for 2 months) on 49 severe or morbid obese patients (37 women, 12 men) and 55 healthy volunteers (39 wome…

AdultErythrocyte AggregationMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Phosphatidylserinesmedicine.disease_causeErythrocyte aggregationFlow cytometrychemistry.chemical_compoundYoung AdultEndocrinologyWeight lossInternal medicineErythrocyte DeformabilityMalondialdehydeWeight LossMedicineErythrocyte deformabilityHumansObesityProtein PrecursorsNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryErythrocyte MembranePhosphatidylserineMiddle AgedMalondialdehydePathophysiologyPeptide FragmentsOxidative StressEndocrinologychemistryCase-Control StudiesImmunologyFemaleProthrombinmedicine.symptombusinessOxidative stress
researchProduct

Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional ele…

2001

Gelatinase A (MMP-2) and gelatinase B (MMP-9) play a key role in the proteolytic cascade leading to ECM degradation during invasion and metastasis. The enzyme activity is regulated both at the intra- and extra-cellular level. Extracellular regulation is achieved mainly through the balance between proenzyme activation and inhibition, which appears to be altered in cancer patients. One of the mechanisms of MMP inhibition is the binding of the enzymes to appropriate tissue inhibitors (TIMP). In the recent literature, it has been suggested that MMP-2 and/or MMP-9 are indeed over-produced in many carcinomas, while the identity of the various enzymatic forms (latent, activated and enzyme/inhibito…

AdultGelatin ZymographyGelatinase AMatrix metalloproteinaseBiologyMetastasisExtracellularmedicineGelatinaseHumansElectrophoresis Gel Two-DimensionalMolecular Biologychemistry.chemical_classificationEnzyme Precursorsmedicine.diseaseMolecular biologyEnzyme assayEnzymeBiochemistrychemistryMatrix Metalloproteinase 9Colonic Neoplasmsbiology.proteinMatrix Metalloproteinase 2Electrophoresis Polyacrylamide GelDensitometryMatrix biology : journal of the International Society for Matrix Biology
researchProduct

Development of a Peptide-Based Sandwich Elisa for Human Tissue Prokallikrein with No Cross-Reactivity from Mature Kallikrein

2000

Human tissue prokallikrein is the enzymatically inactive zymogen of a serine proteinase involved in the liberation of vasoactive kinin peptides, and it is supposed that an impaired prokallikrein-to-kallikrein conversion is closely related to certain hypertensive and inflammatory disorders. Progress in understanding the biological role of the proenzyme has been limited by the absence of an accurate assay for the kallikrein precursor. We describe a sandwich enzyme-linked immunosorbent assay to measure human tissue prokallikrein using monospecific anti-peptide antibodies raised against propeptide derivatives. This method could detect a minimum concentration of 60 pg/ml prokallikrein and displa…

AdultImmunologyTissue kallikreinEnzyme-Linked Immunosorbent AssayPeptideCross Reactionsmedicine.disease_causeSensitivity and SpecificityCross-reactivityZymogenmedicineHumansProtein precursorPharmacologychemistry.chemical_classificationEnzyme Precursorsmedicine.diagnostic_testChemistryReproducibility of ResultsKallikreinKininMolecular biologyPeptide FragmentsBiochemistryImmunoassayKallikreinsJournal of Immunoassay
researchProduct

Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implicati…

1997

The serum levels of lysosomal cathepsin B and L and Stefin A, an intracellular inhibitor of these proteolytic enzymes, were determined in patients with hepatocellular carcinoma (HCC) and/or liver cirrhosis (LC) and correlated with some clinical and biochemical parameters of these diseases. Cathepsin B serum levels were increased in HCC and in LC patients as compared to normal subjects (p < 0.001). However no difference was observed between HCC and LC groups. Interestingly, a significant relationship was evidenced between cathepsin B serum content and the grade of severity of cirrhosis (r = 0.41; p < 0.001). Cathepsin L was significantly elevated only in sera of cancer patients as comp…

AdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyPathologyCirrhosisCarcinoma HepatocellularHepatocellular carcinomaoteinase inhibitorCathepsin LLysosomal proteinaseGastroenterologyCathepsin BLiver cirrhosiCathepsin BCathepsin LInternal medicineEndopeptidasesmedicineCarcinomaHumansCystatin AStefin AAgedTumor progression.Aged 80 and overEnzyme PrecursorsbiologyLiver NeoplasmsProteolytic enzymesCancerGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsPrCysteine EndopeptidasesOncologyCystatin AHepatocellular carcinomabiology.proteinFemalealpha-FetoproteinsLysosomesOncology
researchProduct

Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease act…

1991

. To analyse the relationship between the presence of liver cirrhosis and hepatic inflammation and the serum concentrations of the aminoterminal propeptide of procollagen type III (P-III-NP) and of hyaluronic acid (HA) in chronic liver disease, we measured P-III-NP and HA concentrations in paired serum samples from 133 patients with various chronic liver diseases, from 22 patients with acute hepatitis and from 50 healthy age-matched controls. In 24 (of the 133) patients with autoimmune chronic liver disease, follow-up determination was performed during therapeutic treatment with immunosuppressive drugs. Compared with controls P-III-NP concentrations (medians) were significantly elevated in …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisClinical BiochemistryChronic liver diseaseBiochemistryGastroenterologyAutoimmune DiseasesHepatitisDisease activityDiagnosis Differentialchemistry.chemical_compoundInternal medicineHyaluronic acidmedicineHumansHyaluronic AcidProtein precursorHepatitis ChronicHepatitisChronic Activebusiness.industryLiver DiseasesGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsType III ProcollagenchemistryImmunologyFemalebusinessBiomarkersProcollagenEuropean journal of clinical investigation
researchProduct

Reactivation of chronic type B hepatitis: the effect on expression of serum HBV-DNA and pre-S encoded proteins.

1988

Hepatitis B markers were studied in seven patients with reactivated liver disease. Reactivation of chronic type B hepatitis, as indicated by the reappearance of hepatitis B e antigen (HBeAg) in the serum, was characterised by the appearance of hepatitis B virus-DNA (HBV-DNA) in the serum. The expression of pre-S 1 encoded protein remained unchanged in five of seven patients, and poly-HSA as a marker for pre-S 2 encoded protein remained detectable in six of seven patients before and after reactivation of chronic hepatitis. The level of serum HBV-DNA correlated well with the level of liver enzymes, which rose from normal to various levels after reactivation of the liver disease. The data sugg…

AdultMaleAdolescentBiologyLiver diseaseAntigenVirologymedicineCytotoxic T cellHumansHepatitis B e AntigensProtein PrecursorsHepatitis ChronicHepatitisHepatitis B Surface AntigensHepatobiliary diseaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyInfectious DiseasesHBeAgViral replicationDNA ViralFemaleJournal of medical virology
researchProduct

Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.

2015

Phenotypic improvement of hemoglobinopathies such as sickle cell disease and β-thalassemia (β-thal) has been shown in patients with high levels of Hb F. Among the drugs proposed to increase Hb F production, hydroxyurea (HU) is currently the only one proven to improve the clinical course of these diseases. However, Hb F increase and patient's response are highly variable, indicating that new pharmacological agents could be useful for patients not responding to HU or showing a reduction of response during long-term therapy. In this study we evaluated the efficacy of rapamycin, a lypophilic macrolide used for the prevention of acute rejection in renal transplant recipients, as an inducer of Hb…

AdultMaleAdolescentGenotypeThalassemiaClinical BiochemistryCellDiseaseAnemia Sickle Cellbeta-GlobinsPharmacologyBiologyYoung Adultalpha-GlobinsIn vivomedicineHumansHydroxyureaInducergamma-GlobinsGenetics (clinical)Cells CulturedFetal HemoglobinAgedErythroid Precursor CellsSirolimusBiochemistry (medical)beta-ThalassemiaClinical courseHematologyMiddle Agedmedicine.diseasePhenotypeMolecular biologyIn vitromedicine.anatomical_structureGene Expression RegulationMutationFemaleHemoglobin
researchProduct

Pure Progressive Amnesia and the APPV717G Mutation

2009

We report an isolated, slowly progressive, pure amnestic phenotype in a 59-year-old member of a family affected by autosomal dominant familial Alzheimer disease. Early-onset Alzheimer disease in this family was associated with a V717G mutation in the amyloid precursor protein gene (APP). Subjective impairment of episodic memory began in our subject at the age of 44 years and subsequent, longitudinal neuropsychologic assessment confirmed progressive, severe, global impairment of memory functions over a period of 14 years with preservation of other cognitive domains. The mean annual hippocampal atrophy rate, determined by volumetric magnetic resonance imaging was intermediate between values p…

AdultMaleAgingPathologymedicine.medical_specialtyGlycineAmnesiaHippocampusAmyloid beta-Protein PrecursorAtrophyAlzheimer DiseasemedicineHumansDementiaMemory disorderEpisodic memoryAgedSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitive disorderValineMiddle Agedmedicine.diseaseAPPV717G mutation.PedigreePsychiatry and Mental healthClinical PsychologyPhenotypeMutationDisease ProgressionPure progressive amnesiaFemaleAmnesiaAtrophyGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasePsychologyGerontologyFrontotemporal dementia
researchProduct